SCHEMBL650687

SCHEMBL650687

CCCCN(Cc1ccccc1OC(F)F)Cc1c(-c2ccccc2)nc(-c2ccccc2)n1CCCC

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.40
TSHR P16473 5/20 0.38
KDM4E B2RXH2 6/20 0.35
ALDH1A1 P00352 6/20 0.35
HPGD P15428 6/20 0.35
HSD17B10 Q99714 6/20 0.35
CYP3A4 P08684 4/20 0.35
HDAC1 Q13547 1/20 0.35
BCHE P06276 2/20 0.35
ACHE P22303 2/20 0.35
DRD2 P14416 1/20 0.35
DRD3 P35462 1/20 0.35
ATP4A P20648 2/20 0.34
ATP4B P51164 2/20 0.34
CASR P41180 1/20 0.34
TLR7 Q9NYK1 1/20 0.33
CRHR1 P34998 1/20 0.33
NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649706 0.92 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL651639 0.89 C5AR1 (0.41) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5069962 0.89 BCHE (0.45) C5AR1TSHRBCHEACHECASR
SCHEMBL5137485 0.88 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650011 0.86 C5AR1 (0.38) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL649513 0.86 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135095 0.86 BCHE (0.47) C5AR1BCHEACHE
SCHEMBL650283 0.85 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL648525 0.85 C5AR1 (0.40) C5AR1TSHRCRHR1
SCHEMBL650548 0.85 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed